[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,993
  • Shares Outstanding, K 3,331
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,910 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta -0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.10
  • Most Recent Earnings $-2.88 on 11/12/25
  • Next Earnings Date 05/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-3.90
  • Growth Rate Est. (year over year) +25,715.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4730 +26.49%
on 04/28/26
1.2599 -52.51%
on 04/02/26
-0.6217 (-50.96%)
since 04/01/26
3-Month
0.4730 +26.49%
on 04/28/26
2.0400 -70.67%
on 03/09/26
-1.2317 (-67.31%)
since 01/30/26
52-Week
0.4730 +26.49%
on 04/28/26
22.3600 -97.32%
on 07/31/25
-14.4017 (-96.01%)
since 05/01/25

Most Recent Stories

More News
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

KAPA : 0.5670 (+0.35%)
SANA : 3.27 (-0.61%)
SLXN : 0.5983 (-2.25%)
AEON : 0.8900 (-3.58%)
CRGX : 4.47 (-1.54%)
TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

TRIB : 0.6075 (+1.25%)
STSS : 1.8400 (+3.08%)
SLXN : 0.5983 (-2.25%)
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

SLXN : 0.5983 (-2.25%)
Silexion Therapeutics Corp. Announces 1-for-9 Reverse Share Split to Enhance Nasdaq Compliance and Support Future Growth

Silexion Therapeutics announced a 1-for-9 reverse share split to maintain Nasdaq compliance and support future growth initiatives.Quiver AI SummarySilexion Therapeutics Corp. has announced a 1-for-9 reverse...

SLXN : 0.5983 (-2.25%)
Silexion Therapeutics to Present at Noble Capital Markets Conference on Innovative KRAS-Driven Cancer Treatments

Silexion Therapeutics will present at the Noble Capital Markets Conference on RNAi therapies for KRAS-driven cancers.Quiver AI SummarySilexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotech...

SLXN : 0.5983 (-2.25%)
5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

FBRX : 28.19 (+5.74%)
QSI : 0.9582 (-2.28%)
DUOT : 9.03 (+2.61%)
IBB : 167.27 (-0.84%)
SLXN : 0.5983 (-2.25%)
SPY : 720.65 (+0.28%)
XBI : 130.42 (-0.69%)
ZIM : 26.28 (-0.61%)

Business Summary

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver...

See More

Key Turning Points

3rd Resistance Point 0.6921
2nd Resistance Point 0.6660
1st Resistance Point 0.6322
Last Price 0.5983
1st Support Level 0.5723
2nd Support Level 0.5462
3rd Support Level 0.5124

See More

52-Week High 22.3600
Fibonacci 61.8% 13.9992
Fibonacci 50% 11.4165
Fibonacci 38.2% 8.8338
Last Price 0.5983
52-Week Low 0.4730

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.